Jaguar Health, Inc.
News
Jaguar Health Appoints Industry Veteran to Head Sales for Company's Commercialized Oncology and HIV Products Including October 2024 Launch of Gelclair for Cancer Supportive Care
Accesswire FDA-approved Gelclair® is company's third commercialized prescription productSusan Krizancic appointed to role of National Sales Director at Jaguar family company Napo Pharmaceuticals SAN...\n more…
Jaguar Health to Present at the September 9-11 H.C. Wainwright Annual Global Investment Conference
Accesswire SAN FRANCISCO, CA / ACCESSWIRE / September 6, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will be presenting virtually, and...\n more…
Jaguar Health Celebrates National Service Dog Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs
Accesswire Company's Canalevia®-CA1 prescription drug is FDA conditionally approved for treatment of chemotherapy-induced diarrhea (CID) in dogs and is the first and only treatment for CID in dogs to...\n more…
New Innovators with Jane King Interview with Jaguar Health CEO Lisa Conte Spotlights Company's Near-Term Commercial & Development Milestones
Accesswire Click here to view interview videoParamount near-term activities include planned October 2024 commercial launch of FDA-approved oral mucositis prescription product Gelclair® and results from...\n more…
Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
Accesswire New patent issued for core rare disease target indication for crofelemerNapo has approximately 230 patents issued and pendingJaguar is supporting independent investigator-initiated proof-of-concept...\n more…